Ischemic Stroke Clinical Trial
Official title:
fMRI and Robot-Assisted Practice of Activities of Daily Living
Verified date | February 2014 |
Source | Medical College of Wisconsin |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
The investigators will study motor recovery after robot-assisted therapy after stroke. A small clinical trial will be conducted to quantify the central nervous system changes associated with robotic or standard training, and identify trends across high and low responders in terms of patterns of change in cortical activity and type of white matter connectivity.The investigators hypothesize that robot training will lead to larger improvements as compared to standard occupational therapy. The investigators hypothesize that high responders to the robot training will have reduced compensatory activation in the bilateral area and will connectivity in the motor tracts.
Status | Completed |
Enrollment | 61 |
Est. completion date | June 2013 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 30 Years to 85 Years |
Eligibility |
Inclusion Criteria: Stroke: - 30 to 85 years - Right-handed (evaluated with handedness survey) - suffered a unilateral ischemic stroke in the motor control area, which resulted in hemiparesis of the arm (confirmed by medical data), - at least 6-months post-stroke - residual movement at least (a) 15 degree shoulder flexion or adduction, (b) 15 degree active elbow flexion and extension - not claustrophobic - not depressed (as measured depression survey) - able to use the scanner, i.e., passes the fMRI screening survey - able to understand the instructions and complete the tracking tasks Control - older than 20 years - Right-handed (evaluated with survey) - not claustrophobic - able to use the scanner, i.e., passes the fMRI screening survey - able to understand the instructions and complete the tracking tasks - no history of neurological disorders --not depressed (as measured depression survey) Exclusion Criteria: Stroke: - brain stem, stroke - pre-existing neurological or psychiatric disorders - Spasticity >3 at elbow or fingers on Ashworth - demonstrated visuospatial, language or attention deficits of a severity that prevents understanding the task - shoulder pain or joint pain during movements - synkinetic movements or mirror movements - decline to participate - will not comply with full protocol - pregnant - allergic to goretex and conductivity gel Control - decline to participate - will not comply with full protocol - pregnant - allergic to goretex and conductivity gel |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Clement J Zablocki VA | Milwaukee | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
Medical College of Wisconsin | Marquette University, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), VA Office of Research and Development |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinical Measures: Fugl-Meyer (Motor control), Functional Hand Evaluation (ADL), Jebsen Taylor | Pre (2x) , Post, Follow-Up | No | |
Primary | Biomechanical:Movement Time, Grasp Aperture, Movement Smoothness | Pre (2x), Post, Follow-up | No | |
Primary | Imaging Measures: BOLD response (activation), Laterality Index, Fractional Anisotropy, Fiber Density Index | Pre (1x), Post, Follow-up | No | |
Secondary | Clinical Measures: Joint ROM, MMT, Spasticity | Pre(2x), Post, Follow-up | No | |
Secondary | Clinical Measures: Pain, Exertion | During Therapy | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05196659 -
Collaborative Quality Improvement (C-QIP) Study
|
N/A | |
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03281590 -
Stroke and Cerebrovascular Diseases Registry
|
||
Recruiting |
NCT05518305 -
Platelet Expression of FcγRIIa and Arterial Hemodynamics to Predict Recurrent Stroke in Intracranial Atherosclerosis
|
||
Recruiting |
NCT06029959 -
Stroke and CPAP Outcome Study 3
|
N/A | |
Recruiting |
NCT03728738 -
Zero Degree Head Positioning in Hyperacute Large Artery Ischemic Stroke
|
Phase 3 | |
Terminated |
NCT03396419 -
IMPACT- 24col Collateral Blood Flow Assessment Following SPG Stimulation in Acute Ischemic Stroke (ImpACT-24B Sub-Study)
|
||
Recruiting |
NCT05065216 -
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04897334 -
Transcranial Direct Current Stimulation and Rehabilitation to Ameliorate Impairments in Neurocognition After Stroke
|
N/A | |
Not yet recruiting |
NCT06462599 -
Osteopontin Gene Polymorphism in Stroke Patients in Egypt
|
||
Not yet recruiting |
NCT06032819 -
Differentiating Between Brain Hemorrhage and Contrast
|
||
Not yet recruiting |
NCT06026696 -
Cohort of Neurovascular Diseases Treated in the Acute Phase and Followed at Lariboisière
|
||
Recruiting |
NCT02910180 -
Genetic, Metabolic, and Growth Factor Repository for Cerebrovascular Disorders
|
||
Completed |
NCT03554642 -
Walkbot Robotic Training for Improvement in Gait
|
Phase 3 | |
Completed |
NCT02922452 -
A Study to Evaluate the Effect of Diltiazem on the Pharmacokinetics (PK) of BMS-986141 in Healthy Subjects
|
Phase 1 | |
Withdrawn |
NCT01866189 -
Identification of Hypoxic Brain Tissues by F-MISO PET in Acute Ischemic Stroke
|
N/A | |
Recruiting |
NCT03041753 -
Reperfusion Injury After Stroke Study
|
N/A | |
Completed |
NCT02549846 -
AdminiStration of Statin On Acute Ischemic stRoke patienT Trial
|
Phase 4 | |
Completed |
NCT02610803 -
Paroxysmal Atrial Fibrillation in Patients With Acute Ischemic Stroke
|
N/A | |
Completed |
NCT01678534 -
Reparative Therapy in Acute Ischemic Stroke With Allogenic Mesenchymal Stem Cells From Adipose Tissue, Safety Assessment, a Randomised, Double Blind Placebo Controlled Single Center Pilot Clinical Trial
|
Phase 2 |